Explore the latest in anticoagulation from The JAMA Network, including dosing, safety, and reversal of newer oral agents, periprocedural management, and more.
This systematic review uses the MEDLINE and EMBASE databases to identify the available therapies for livedoid vasculopathy and their clinical outcomes.
A 75-year-old woman recently diagnosed as having stage IV lung adenocarcinoma was admitted for dyspnea and weakness. Transthoracic echocardiogram showed normal biventricular function with normal wall motion and shaggy, bulky masses on the tips of both mitral valve leaflets. What would you do next?
This population-based cohort study uses the Norwegian national registries to determine the association between warfarin use and cancer incidence among persons aged 52 to 82 years.
This secondary analysis reports on the association of low-dose and standard-dose intravenous alteplase treatment with age, ethnicity (Asian vs non-Asian), and severity of acute ischemic stroke among patients in the ENCHANTED randomized clinical trial.
This systematic review and meta-analysis compares the clinical effectiveness of coronary computed tomography angiography with that of functional stress testing for patients with suspected coronary artery disease.
This study assesses whether anti–factor Xa–guided dosing, compared with standard dosing, reduces the rate of venous thromboembolism in adults admitted to a level I trauma intensive care unit.
This randomized clinical trial evaluates whether chewing a loading dose of ticagrelor, 180 mg, vs traditional oral administration of an equal dose enhances platelet inhibition at 30 minutes and 1 hour after loading dose administration in patients with ST-segment elevation myocardial infarction.
This cohort study uses data from the Taiwan National Health Insurance database to assess the association between use of non–vitamin K oral anticoagulants with vs without concurrent medications and risk of major bleeding in patients with nonvalvular atrial fibrillation.
This population-based study characterize rates of hematuria-related complications among patients taking antithrombotic medications.
This randomized clinical trial examines whether rivaroxaban or warfarin sodium is safer and more effective for preventing early recurrent stroke in patients with atrial fibrillation–related acute ischemic stroke.
This randomized clinical trial compares clinically guided vs genotype-guided dosing to assess whether it improves the safety of warfarin initiation in patients undergoing elective hip or knee arthroplasty.
This systematic review and meta-analysis of phase 3 randomized clinical trials characterizes the risk of intraocular bleeding with novel oral anticoagulants compared with warfarin.
This observational cohort study examines the differences between treating patients with atrial fibrillation with 1 stroke risk factor with nonvitamin K antagonist oral anticoagulants vs warfarin.
This Viewpoint discusses the management of antiplatelet therapy in patients with coronary stents undergoing elective noncardiac surgery.
This secondary analysis of the EUROMAX randomized clinical trial assesses the effect of bivalirudin vs heparin plus optional glycoprotein IIb/IIIa inhibitors on 1-year mortality in patients with ST-segment elevation myocardial infarction.
This secondary analysis of a randomized clinical trial assesses whether a link exists between the length of procedure time and acute stent thrombosis in patients treated with bivalirudin vs heparin plus glycoprotein IIb/IIIa inhibitor.
This case report of a woman in her 80s is a reminder that fresh frozen plasma transfusions in certain patients with nonurgent conditions can lead to transfusion-associated circulatory overload.
This JAMA Clinical Guidelines Synopsis summarizes the American College of Chest Physicians’ 2016 recommendations on antithrombotic therapy for venous thromboembolism (VTE).